See more : Marudai Food Co., Ltd. (2288.T) Income Statement Analysis – Financial Results
Complete financial analysis of Biora Therapeutics, Inc. (BIOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biora Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- COSCIENS Biopharma Inc. (CSCI) Income Statement Analysis – Financial Results
- INTAGE HOLDINGS Inc. (4326.T) Income Statement Analysis – Financial Results
- Freelancer Limited (FLN.AX) Income Statement Analysis – Financial Results
- Sonder Holdings Inc. (SOND) Income Statement Analysis – Financial Results
- Cel AI PLC (CLAI.L) Income Statement Analysis – Financial Results
Biora Therapeutics, Inc. (BIOR)
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 4.00K | 305.00K | 1.25M | 74.31M | 143.99M | 127.97M |
| Cost of Revenue | 0.00 | 907.00K | 1.44M | 93.43M | 100.49M | 92.08M |
| Gross Profit | 4.00K | -602.00K | -190.00K | -19.12M | 43.49M | 35.90M |
| Gross Profit Ratio | 100.00% | -197.38% | -15.24% | -25.73% | 30.21% | 28.05% |
| Research & Development | 29.84M | 24.05M | 45.79M | 47.74M | 63.40M | 48.71M |
| General & Administrative | 0.00 | 0.00 | 68.54M | 75.44M | 61.32M | 51.24M |
| Selling & Marketing | 0.00 | 0.00 | 4.76M | 52.89M | 58.89M | 50.19M |
| SG&A | 37.31M | 38.04M | 73.30M | 128.33M | 120.21M | 101.43M |
| Other Expenses | 0.00 | 2.62M | 5.99M | -25.08M | 0.00 | 0.00 |
| Operating Expenses | 67.15M | 62.09M | 119.08M | 176.07M | 183.61M | 150.14M |
| Cost & Expenses | 67.15M | 62.09M | 119.08M | 269.50M | 284.10M | 242.21M |
| Interest Income | 0.00 | 10.99M | 12.64M | 9.92M | 575.00K | 1.80M |
| Interest Expense | 9.82M | 10.99M | 12.64M | 34.87M | 9.20M | 9.09M |
| Depreciation & Amortization | 555.00K | 907.00K | 1.44M | 1.44M | 4.60M | 4.60M |
| EBITDA | -114.05M | -37.35M | -164.57M | -106.18M | -135.44M | -110.17M |
| EBITDA Ratio | -2,851,350.00% | -19,398.03% | -5,106.66% | -262.66% | -92.51% | -84.93% |
| Operating Income | -67.14M | -61.78M | -117.84M | -195.19M | -140.12M | -114.24M |
| Operating Income Ratio | -1,678,575.00% | -20,256.07% | -9,449.64% | -262.66% | -97.31% | -89.27% |
| Total Other Income/Expenses | -57.28M | 12.53M | -60.80M | -35.00M | -8.62M | -9.62M |
| Income Before Tax | -124.42M | -49.25M | -178.64M | -230.06M | -148.74M | -123.86M |
| Income Before Tax Ratio | -3,110,600.00% | -16,147.54% | -14,325.58% | -309.58% | -103.30% | -96.78% |
| Income Tax Expense | -90.00K | -420.00K | -119.00K | -37.53M | -706.00K | 5.25M |
| Net Income | -124.12M | -48.83M | -178.52M | -192.53M | -148.04M | -129.11M |
| Net Income Ratio | -3,102,875.00% | -16,009.84% | -14,316.04% | -259.08% | -102.81% | -100.88% |
| EPS | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| EPS Diluted | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| Weighted Avg Shares Out | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
| Weighted Avg Shares Out (Dil) | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
Biora Therapeutics Provides Outlook for 2024
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Source: https://incomestatements.info
Category: Stock Reports